BiotechTube

Vapendavir + Vapendavir + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Feb 1, 2015 → Dec 1, 2016

NCT ID
NCT02367313

About Vapendavir + Vapendavir + Placebo

Vapendavir + Vapendavir + Placebo is a phase 2 stage product being developed by Vaxart for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02367313. Target conditions include Asthma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02367313Phase 2Completed

Competing Products

20 competing products in Asthma

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
77
DuleraMerckApproved
85
BriquilimabJasper TherapeuticsPhase 1
25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
52
RoflumilastAstraZenecaPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
52
Regadenoson + PlaceboAstellas PharmaApproved
85
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
77
rabeprazoleEisaiPhase 3
77
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
Placebo + BrodalumabKyowa KirinPhase 2
52
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
52
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77

Other Products from Vaxart

VXA-A1.1 + Fluzone®Phase 2
44
Vapendavir + Placebo Oral TabletPhase 2
44
VXA-CoV2-1.1-SPhase 2
44
BTA798 + PlaceboPhase 2
44
40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + PlaceboPhase 2
44